enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update
enVVeno Medical (US:NVNO) Accessnewswireยท2025-10-31 12:05Core Insights - The company has sufficient cash and investments to fund current operations through Q2 2027, excluding VenoValve commercialization and the enVVe IDE study [1] - The cash burn for Q3 2025 was $4.2 million, which aligns with the projected quarterly range [1] - The company is engaged in an ongoing appeal with the FDA regarding the VenoValve PMA decision, with feedback anticipated by the end of 2025 [1] Financial Summary - The company ended Q3 2025 with $31.0 million in cash and investments [1]